Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

The Remission Clinic approach to halt the progression of kidney disease.

Remission Clinic Task Force; Clinical Research Center "Aldo e Cele Daccò".

J Nephrol. 2011 May-Jun;24(3):274-81. doi: 10.5301/JN.2011.7763.

PMID:
21534237
2.

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.

Remuzzi G, Perico N, Macia M, Ruggenenti P.

Kidney Int Suppl. 2005 Dec;(99):S57-65. Review.

PMID:
16336578
3.
4.

Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.

Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S250-4. Review.

5.

Recent changes in the landscape of combination RAS blockade.

Epstein BJ, Smith SM, Choksi R.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127. Review.

PMID:
19900020
6.

Can dual blockade of the renin-angiotensin system reduce progression of kidney disease beyond monotherapy?

Brewster UC, Perazella MA.

Expert Opin Drug Saf. 2004 Jan;3(1):9-23. Review.

PMID:
14680458
7.

Therapeutic measures in proteinuric nephropathy.

Praga M.

Kidney Int Suppl. 2005 Dec;(99):S137-41. Review.

PMID:
16336567
8.
9.

Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.

Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F1203-11. doi: 10.1152/ajprenal.00045.2010. Epub 2010 Aug 18.

11.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
12.

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.

Kunz R, Friedrich C, Wolbers M, Mann JF.

Ann Intern Med. 2008 Jan 1;148(1):30-48. Epub 2007 Nov 5.

PMID:
17984482
13.

Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.

Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.

Kidney Int Suppl. 2002 Dec;(82):S47-52.

15.
16.

Kidney failure stabilizes after an increase over 2 decades.

Cravedi P, Ruggenenti P, Remuzzi G.

J Ren Care. 2007 Jul-Sep;33(3):100-4. Review.

PMID:
19160879
18.

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.

Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51. doi: 10.2215/CJN.04750908. Epub 2009 Mar 4. Review.

19.

Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.

Bianchi S, Bigazzi R, Campese VM.

Am J Kidney Dis. 2010 Apr;55(4):671-81. doi: 10.1053/j.ajkd.2009.11.006. Epub 2010 Jan 25.

PMID:
20097461
20.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.

Am J Kidney Dis. 2006 Jul;48(1):8-20. Review.

PMID:
16797382

Supplemental Content

Support Center